Is Exelixis, Inc. (EXEL) a good stock to buy?

Olyth's institutional analysis of EXEL reveals an Altman Z-Score of 12.62 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($2.32B most recent), help investors decide if EXEL fits their risk profile.

What is the current P/E ratio for EXEL?

As of the latest trading session, Exelixis, Inc. (EXEL) has a trailing P/E ratio of 15.34.

Who is the CEO of Exelixis, Inc.?

The current Chief Executive Officer of Exelixis, Inc. is Michael Morrissey.

What was EXEL's revenue for the last 5 years?

According to its latest income statements, Exelixis, Inc. reported annual revenues of $2.32B (2026), $2.17B (2025), $1.83B (2023), $1.61B (2022), $1.43B (2021) respectively.

Does EXEL pay a dividend?

Exelixis, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does EXEL have?

In its latest reporting period, Exelixis, Inc. generated $0.84B in Free Cash Flow against a total debt load of $0.17B.

What is the Price-to-Book (P/B) ratio of Exelixis, Inc.?

The Price-to-Book (P/B) ratio for Exelixis, Inc. (EXEL) is currently 5.55.

What is the Price-to-Sales (P/S) ratio of EXEL?

Based on trailing twelve-month data, Exelixis, Inc. (EXEL) trades at a Price-to-Sales (P/S) ratio of 5.11.

What is Exelixis, Inc.'s Return on Equity (ROE)?

Exelixis, Inc. (EXEL) has a Return on Equity (ROE) of 36.89%, representing its profitability relative to shareholder equity.

EXEL

Exelixis, Inc. · Healthcare

44.20

0.50%(+0.22)

Market Open

Last Updated: — ET

52W L: $32.3852W H: $49.62

$44.18

CHG+3.37 (+8.26%)

H$44.39

L$40.05

VOL38M

EXEL (1h)

Company Profile

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Sector

Healthcare

Industry

Biotechnology

Employees

1,147

IPO Date

2000-04-17

Beta

0.42

Websitewww.exelixis.com↗

EXEL

SG Americas Securities LLC Buys 15,203 Shares of Exelixis, Inc. $EXEL

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis: A Strong Contender in the Cancer Drug Market

Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Recommendation of “Hold” from Analysts

Here's Why Exelixis (EXEL) is a Strong Value Stock